Varying degrees of survival benefit and delay of disease progression in patients with lung adenocarcinoma can be achieved no matter PD-1/PD-L1 inhibitors are used alone or in combination with chemotherapy and molecular targeted therapy. This evidence concerns the gene PDCD1 and lung adenocarcinoma.